Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. YCBD
stocks logo

YCBD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2026Q1
4.70M
+3.2%
-0.160
-86.67%
5.29M
+3.49%
-0.050
-97.16%
Estimates Revision
The market is revising No Change the revenue expectations for cbdMD, Inc. (YCBD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -16.30%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-16.30%
In Past 3 Month
Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.611
sliders
Low
2.00
Averages
2.00
High
2.00
Current: 0.611
sliders
Low
2.00
Averages
2.00
High
2.00
Maxim
Buy
downgrade
$3 -> $2
2025-08-20
Reason
Maxim
Price Target
$3 -> $2
2025-08-20
downgrade
Buy
Reason
Maxim lowered the firm's price target on cbdMD to $2 from $3 and keeps a Buy rating on the shares. The firm cites the company's Q3 loss coming in wider than expected amid softness in demand and regulatory uncertainties, the analyst tells investors in a research note. Maxim adds that while the company has partnered with industry advocacy groups to engage legislators and prioritize compliance with product quality and labeling requirements, it expects regulatory headwinds to persist, limiting growth through 2026.
Maxim
Buy
downgrade
$16 -> $3
2025-05-22
Reason
Maxim
Price Target
$16 -> $3
2025-05-22
downgrade
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for cbdMD Inc (YCBD.A) is -2.78, compared to its 5-year average forward P/E of -5.72. For a more detailed relative valuation and DCF analysis to assess cbdMD Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.72
Current PE
-2.78
Overvalued PE
7.05
Undervalued PE
-18.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-54.26
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
127.20
Undervalued EV/EBITDA
-235.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.96
Current PS
0.00
Overvalued PS
2.15
Undervalued PS
-0.23
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

YCBD News & Events

Events Timeline

(ET)
2025-11-21
08:32:38
cbdMD projects FY25 revenue between $19.1M and $19.3M, down from $19.5M last year
select
2025-10-09 (ET)
2025-10-09
10:05:50
cbdMD's Herbal Oasis Forms Distribution Alliance with Bevtalk
select
2025-04-22 (ET)
2025-04-22
10:19:29
cbdMD announces automatic conversion of shares, 1-for-8 reverse stock split
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-21Newsfilter
cbdMD Announces Initial Unaudited Results for Fourth Quarter and Fiscal Year 2025

  • Financial Performance Overview: cbdMD, Inc. expects fiscal 2025 net sales revenue to be between $19.1 and $19.3 million, slightly down from $19.5 million in fiscal 2024, while fourth-quarter sales are projected to increase to between $4.7 and $4.9 million.

  • Net Loss Improvement: The company's net loss for fiscal 2025 is anticipated to improve significantly, ranging from $1.9 to $2.1 million, compared to a loss of $3.7 million in the previous year.

  • Strategic Actions and Growth: cbdMD has implemented strategies to strengthen its business model, resulting in positive revenue growth in the fourth quarter and a stable year-over-year sales performance, contrasting with declines reported by many competitors.

  • Future Outlook: The company expresses confidence in its ability to achieve continued earnings improvement through disciplined cost management and a focus on profitable growth, with an upcoming earnings call scheduled for mid-December.

[object Object]
Preview
9.0
04-11Benzinga
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket

  • argenx SE Stock Surge: Shares of argenx SE rose 5.1% in pre-market trading following FDA approval of VYVGART Hytrulo for self-injection in treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

  • Pre-Market Stock Movements: Several stocks saw significant changes in pre-market trading, with MSP Recovery, Inc. gaining 167%, while AlTi Global, Inc. experienced a sharp decline of 57.3%.

[object Object]
Preview
9.0
04-11Yahoo Finance
cbdMD, Inc. Announces Shareholder Approval of Automatic Conversion of Series A Preferred Stock and Other Results from Annual Meeting

  • Automatic Conversion of Preferred Stock: cbdMD, Inc. announced the approval of the automatic conversion of its 8% Series A Cumulative Convertible Preferred Stock into Common Stock, which will eliminate approximately $6.7 million in accrued dividends and $4 million in annual obligations, enhancing the company's capital structure.

  • Annual Meeting Outcomes: At the annual meeting, shareholders elected seven directors, ratified the appointment of an independent accounting firm, and approved a potential reverse stock split of common stock within a specified ratio before the next annual meeting.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is cbdMD Inc (YCBD) stock price today?

The current price of YCBD is 0.6114 USD — it has increased 3.21 % in the last trading day.

arrow icon

What is cbdMD Inc (YCBD)'s business?

cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.

arrow icon

What is the price predicton of YCBD Stock?

Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is cbdMD Inc (YCBD)'s revenue for the last quarter?

cbdMD Inc revenue for the last quarter amounts to 4.61M USD, decreased -10.96 % YoY.

arrow icon

What is cbdMD Inc (YCBD)'s earnings per share (EPS) for the last quarter?

cbdMD Inc. EPS for the last quarter amounts to -0.21 USD, decreased -82.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for cbdMD Inc (YCBD)'s fundamentals?

The market is revising No Change the revenue expectations for cbdMD, Inc. (YCBD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -16.30%.
arrow icon

How many employees does cbdMD Inc (YCBD). have?

cbdMD Inc (YCBD) has 42 emplpoyees as of December 05 2025.

arrow icon

What is cbdMD Inc (YCBD) market cap?

Today YCBD has the market capitalization of 5.29M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free